Kiselev V.I. 1
Drukh V.M. 1
Kuznetsov I.N. 2
Muyzhnek E.L. 3
Gorbunova E.A. 4
Pchelintseva O.I. 1
1 Peoples’ Friendship University of Russia (PFUR)
2 Moscow State Medical Stomatological University (MGMSU) n.a. A. I. Evdokimov.
3 ZAO «MiraxBioPharma»
4 Research Center for Obstetrics
This preclinical study was carried out to estimate pharmacokinetics and relative bioavailability of a new pharmaceutical composition with a high bioavailability comprising 3,3’-diindolylmethane (DIM) and pluronic. A new formulation and pure DIM substance were tested in 98 rats. These substances were intragastrically administered to animals in the doses of 60 mg/kg. Concentrations of DIM in blood plasma were measured by HPLC. Besides, pharmacokinetic parameters were determined. It was shown that Cmax of the pure DIM substance achieved 0,21±0,02 μg/ml , when Cmax of a new pharmaceutical composition based on DIM reached 3,23±0,12 μg/ml. Bioavailability of a new pharmaceutical formulation was about 17,8-fold higher compared to pure DIM substance.